Psychedelic compounds like psilocybin, MDMA, LSD, and DMT show promise for treating mental health conditions, with the FDA granting Breakthrough Therapy designations for several uses. Despite this, most remain Schedule I under the Controlled Substances Act, indicating no accepted medical use and high abuse potential, which imposes strict regulations. Over 150 active clinical trials are assessing their safety and efficacy, and federal research agencies, bipartisan congressional activities, and state-level reforms support their medical applications. A recent Executive Order calls for federal reforms to accelerate research and access, including timely rescheduling after Phase 3 trials. Rescheduling could reduce costs and administrative barriers while maintaining safety. The article outlines potential paths for rescheduling various Schedule I psychedelics given emerging clinical applications.
Research on Schedule I substances in the United States is heavily restricted by the Controlled Substances Act, creating what is termed Research Harm—the restriction or deterrence of legitimate scientific inquiry due to governmental regulatory controls and criminal prohibitions. Barriers include lengthy DEA registration timelines, inconsistent guidance, and policy confusion, limiting access to substances with therapeutic potential like psilocybin, MDMA, cannabis, and DOI. The 2025 HALT Fentanyl Act introduces procedural improvements such as expedited registration and shared institutional access but leaves key regulatory issues unresolved. Recommended reforms include revising medical utility interpretations, conducting periodic evidence reviews, and establishing a scheduling framework for easier research access.